Comparison of the effectiveness of esflurbiprofen patch with celecoxib tablet in patients after total knee arthroplasty, a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250625003

Enrollment

100

Registered

2025-06-25

Start date

2024-10-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

An esflurbiprofen patch can control pain in patients after total knee arthroplasty as effectively as a celecoxib tablet. Esflurbiprofen patch, Celecoxib tablet, Pain Management, Total knee arthroplasty

Interventions

esflurbiprofen patch,celecoxib tablet

Experimental Drug,Active Comparator Drug

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 50 years old 2. Diagnosed with Knee osteoarthritis and has an appointment for surgery in total knee arthroplasty

Exclusion criteria

Exclusion criteria: 1. Previous surgery on the same knee within the last 6 months 2. Prior use of NSAIDs within 1 week before surgery 3. Known allergy to the drugs used in this trial 4. Severe gastrointestinal disorders such as severe abdominal pain, hematemesis, and hematochezia 5. Serious concomitant medical illness or major co-morbidity precluding aerobic exercise at 50-60%maximum heart rate. 6. Major neurological conditions. 7. Inability to communicate or unwilling to give informed consent

Design outcomes

Primary

Measure	Time frame
Difference VAS pain score at rest at 14 days follow up VAS score,Difference VAS pain score at motion at 14 days follow up VAS score	—

Secondary

Measure	Time frame
Difference VAS pain score at rest at 6 weeks follow up VAS score,Difference VAS pain score at motion at 6 weeks follow up VAS score,Range of knee motion at 14 days follow up goniometer,Range of knee motion at 6 weeks follow up goniometer,Performance-based measures at 14 days follow up Time up and go,Performance-based measures at 6 weeks follow up Time up and go,Patient-reported outcome measures at 14 days follow up Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index,Patient-reported outcome measures at 6 weeks follow up Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index,Performance-based measures at 14 days follow up Five times sit to stand,Performance-based measures at 6 weeks follow up Five times sit to stand,Performance-based measures at 14 days follow up 3-minute walk test,Performance-based measures at 14 days follow up 3-minute walk test,Adverse drug events at 14 days follow up clinical and lab serum creatinine,Adverse drug events at 6 weeks follow up clinical and lab serum creatinine,Patient-reported outcome measures at 14 days follow up SF-12,Patient-reported outcome measures at 6 weeks follow up SF-12	—

Measure

Time frame

Difference VAS pain score at rest at 6 weeks follow up VAS score,Difference VAS pain score at motion at 6 weeks follow up VAS score,Range of knee motion at 14 days follow up goniometer,Range of knee motion at 6 weeks follow up goniometer,Performance-based measures at 14 days follow up Time up and go,Performance-based measures at 6 weeks follow up Time up and go,Patient-reported outcome measures at 14 days follow up Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index,Patient-reported outcome measures at 6 weeks follow up Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index,Performance-based measures at 14 days follow up Five times sit to stand,Performance-based measures at 6 weeks follow up Five times sit to stand,Performance-based measures at 14 days follow up 3-minute walk test,Performance-based measures at 14 days follow up 3-minute walk test,Adverse drug events at 14 days follow up clinical and lab serum creatinine,Adverse drug events at 6 weeks follow up clinical and lab serum creatinine,Patient-reported outcome measures at 14 days follow up SF-12,Patient-reported outcome measures at 6 weeks follow up SF-12

—

Countries

Thailand

Contacts

Public ContactRachata Piriyamanun

Faculty of medicine, Chulalongkorn University

rachata02626@gmail.com0845525677

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026